Rheumatoid Arthritis Drugs Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Therapeutic Molecule (Pharmaceuticals, Biopharmaceuticals); Route of Administration (Oral, Parenteral)

Report Code: TIPRE00013513 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET INTRODUCTION

Rheumatoid arthritis is a chronic inflammatory disorder that can affect more than just your joints. In some people, the condition can damage a wide variety of body systems, including the skin, eyes, lungs, heart and blood vessels.

MARKET DYNAMICS

The rheumatoid arthritis drugs market is driving due to the rise in incidence of rheumatoid arthritis and upsurge in geriatric population. However, side effects associated with the medication and higher cost of biologics & biosimilars restrain the growth of rheumatoid arthritis drug market.

MARKET SCOPE

The "Rheumatoid Arthritis Drugs Market Analysis to 2028" is a specialized and in-depth study of the medical device industry with a special focus on the global market trend analysis. The report aims to provide an overview of rheumatoid arthritis drugs market with detailed market segmentation by therapy and cancer type. The rheumatoid arthritis drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in rheumatoid arthritis drugs market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The rheumatoid arthritis drugs market is segmented on the basis by therapeutic molecule and route of administration. On the basis of therapeutic molecule, the market is categorized as pharmaceuticals, biopharmaceuticals. Pharmaceuticals segment is further segmented into NSAIDs, analgesics, DMARDs and corticosteroids. Biopharmaceuticals segment is further segmented into biologics and biosimilars. On the basis of route of administration, the market is categorized oral and parenteral.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the rheumatoid arthritis drugs market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The rheumatoid arthritis drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting rheumatoid arthritis drugs market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors affecting the rheumatoid arthritis drugs market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the rheumatoid arthritis drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from rheumatoid arthritis drugs market are anticipated to have lucrative growth opportunities in the future with the rising demand for rheumatoid arthritis drugs in the global market. Below mentioned is the list of few companies engaged in the rheumatoid arthritis drugs market.

The report also includes the profiles of key players in rheumatoid arthritis drugs market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •  AbbVie Inc.
  •  Boehringer Ingelheim GmbH
  •  Novartis AG
  •  Regeneron Pharmaceuticals, Inc.
  •  Pfizer, Inc.
  •  Johnson & Johnsons Services, Inc
  •  Bristol-Myers Squibb Company
  •  F. Hoffmann-La Roche Ltd.
  •  Celegene Corporations
  •  MedImmune, LLC

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Rheumatoid Arthritis Drugs Market - By Therapeutic Molecule
1.3.2 Rheumatoid Arthritis Drugs Market - By Route of Administration
1.3.3 Rheumatoid Arthritis Drugs Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. RHEUMATOID ARTHRITIS DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. RHEUMATOID ARTHRITIS DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. RHEUMATOID ARTHRITIS DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. RHEUMATOID ARTHRITIS DRUGS - GLOBAL MARKET OVERVIEW
6.2. RHEUMATOID ARTHRITIS DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. RHEUMATOID ARTHRITIS DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - THERAPEUTIC MOLECULE
7.1. OVERVIEW
7.2. THERAPEUTIC MOLECULE MARKET FORECASTS AND ANALYSIS
7.3. PHARMACEUTICALS
7.3.1. Overview
7.3.2. Pharmaceuticals Market Forecast and Analysis
7.3.3. NSAIDs Market
7.3.3.1. Overview
7.3.3.2. NSAIDs Market Forecast and Analysis
7.3.4. Analgesics Market
7.3.4.1. Overview
7.3.4.2. Analgesics Market Forecast and Analysis
7.3.5. DMARDs Market
7.3.5.1. Overview
7.3.5.2. DMARDs Market Forecast and Analysis
7.3.6. Corticosteroids Market
7.3.6.1. Overview
7.3.6.2. Corticosteroids Market Forecast and Analysis
7.4. BIOPHARMACEUTICALS
7.4.1. Overview
7.4.2. Biopharmaceuticals Market Forecast and Analysis
7.4.3. Biologics Market
7.4.3.1. Overview
7.4.3.2. Biologics Market Forecast and Analysis
7.4.4. Biosimilars Market
7.4.4.1. Overview
7.4.4.2. Biosimilars Market Forecast and Analysis
8. RHEUMATOID ARTHRITIS DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - ROUTE OF ADMINISTRATION
8.1. OVERVIEW
8.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
8.3. ORAL
8.3.1. Overview
8.3.2. Oral Market Forecast and Analysis
8.4. PARENTERAL
8.4.1. Overview
8.4.2. Parenteral Market Forecast and Analysis
9. RHEUMATOID ARTHRITIS DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Rheumatoid Arthritis Drugs Market Overview
9.1.2 North America Rheumatoid Arthritis Drugs Market Forecasts and Analysis
9.1.3 North America Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Therapeutic Molecule
9.1.4 North America Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Route of Administration
9.1.5 North America Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Countries
9.1.5.1 United States Rheumatoid Arthritis Drugs Market
9.1.5.1.1 United States Rheumatoid Arthritis Drugs Market by Therapeutic Molecule
9.1.5.1.2 United States Rheumatoid Arthritis Drugs Market by Route of Administration
9.1.5.2 Canada Rheumatoid Arthritis Drugs Market
9.1.5.2.1 Canada Rheumatoid Arthritis Drugs Market by Therapeutic Molecule
9.1.5.2.2 Canada Rheumatoid Arthritis Drugs Market by Route of Administration
9.1.5.3 Mexico Rheumatoid Arthritis Drugs Market
9.1.5.3.1 Mexico Rheumatoid Arthritis Drugs Market by Therapeutic Molecule
9.1.5.3.2 Mexico Rheumatoid Arthritis Drugs Market by Route of Administration
9.2. EUROPE
9.2.1 Europe Rheumatoid Arthritis Drugs Market Overview
9.2.2 Europe Rheumatoid Arthritis Drugs Market Forecasts and Analysis
9.2.3 Europe Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Therapeutic Molecule
9.2.4 Europe Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Route of Administration
9.2.5 Europe Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Rheumatoid Arthritis Drugs Market
9.2.5.1.1 Germany Rheumatoid Arthritis Drugs Market by Therapeutic Molecule
9.2.5.1.2 Germany Rheumatoid Arthritis Drugs Market by Route of Administration
9.2.5.2 France Rheumatoid Arthritis Drugs Market
9.2.5.2.1 France Rheumatoid Arthritis Drugs Market by Therapeutic Molecule
9.2.5.2.2 France Rheumatoid Arthritis Drugs Market by Route of Administration
9.2.5.3 Italy Rheumatoid Arthritis Drugs Market
9.2.5.3.1 Italy Rheumatoid Arthritis Drugs Market by Therapeutic Molecule
9.2.5.3.2 Italy Rheumatoid Arthritis Drugs Market by Route of Administration
9.2.5.4 Spain Rheumatoid Arthritis Drugs Market
9.2.5.4.1 Spain Rheumatoid Arthritis Drugs Market by Therapeutic Molecule
9.2.5.4.2 Spain Rheumatoid Arthritis Drugs Market by Route of Administration
9.2.5.5 United Kingdom Rheumatoid Arthritis Drugs Market
9.2.5.5.1 United Kingdom Rheumatoid Arthritis Drugs Market by Therapeutic Molecule
9.2.5.5.2 United Kingdom Rheumatoid Arthritis Drugs Market by Route of Administration
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Rheumatoid Arthritis Drugs Market Overview
9.3.2 Asia-Pacific Rheumatoid Arthritis Drugs Market Forecasts and Analysis
9.3.3 Asia-Pacific Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Therapeutic Molecule
9.3.4 Asia-Pacific Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Route of Administration
9.3.5 Asia-Pacific Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Rheumatoid Arthritis Drugs Market
9.3.5.1.1 Australia Rheumatoid Arthritis Drugs Market by Therapeutic Molecule
9.3.5.1.2 Australia Rheumatoid Arthritis Drugs Market by Route of Administration
9.3.5.2 China Rheumatoid Arthritis Drugs Market
9.3.5.2.1 China Rheumatoid Arthritis Drugs Market by Therapeutic Molecule
9.3.5.2.2 China Rheumatoid Arthritis Drugs Market by Route of Administration
9.3.5.3 India Rheumatoid Arthritis Drugs Market
9.3.5.3.1 India Rheumatoid Arthritis Drugs Market by Therapeutic Molecule
9.3.5.3.2 India Rheumatoid Arthritis Drugs Market by Route of Administration
9.3.5.4 Japan Rheumatoid Arthritis Drugs Market
9.3.5.4.1 Japan Rheumatoid Arthritis Drugs Market by Therapeutic Molecule
9.3.5.4.2 Japan Rheumatoid Arthritis Drugs Market by Route of Administration
9.3.5.5 South Korea Rheumatoid Arthritis Drugs Market
9.3.5.5.1 South Korea Rheumatoid Arthritis Drugs Market by Therapeutic Molecule
9.3.5.5.2 South Korea Rheumatoid Arthritis Drugs Market by Route of Administration
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Rheumatoid Arthritis Drugs Market Overview
9.4.2 Middle East and Africa Rheumatoid Arthritis Drugs Market Forecasts and Analysis
9.4.3 Middle East and Africa Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Therapeutic Molecule
9.4.4 Middle East and Africa Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Route of Administration
9.4.5 Middle East and Africa Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Rheumatoid Arthritis Drugs Market
9.4.5.1.1 South Africa Rheumatoid Arthritis Drugs Market by Therapeutic Molecule
9.4.5.1.2 South Africa Rheumatoid Arthritis Drugs Market by Route of Administration
9.4.5.2 Saudi Arabia Rheumatoid Arthritis Drugs Market
9.4.5.2.1 Saudi Arabia Rheumatoid Arthritis Drugs Market by Therapeutic Molecule
9.4.5.2.2 Saudi Arabia Rheumatoid Arthritis Drugs Market by Route of Administration
9.4.5.3 U.A.E Rheumatoid Arthritis Drugs Market
9.4.5.3.1 U.A.E Rheumatoid Arthritis Drugs Market by Therapeutic Molecule
9.4.5.3.2 U.A.E Rheumatoid Arthritis Drugs Market by Route of Administration
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Rheumatoid Arthritis Drugs Market Overview
9.5.2 South and Central America Rheumatoid Arthritis Drugs Market Forecasts and Analysis
9.5.3 South and Central America Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Therapeutic Molecule
9.5.4 South and Central America Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Route of Administration
9.5.5 South and Central America Rheumatoid Arthritis Drugs Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Rheumatoid Arthritis Drugs Market
9.5.5.1.1 Brazil Rheumatoid Arthritis Drugs Market by Therapeutic Molecule
9.5.5.1.2 Brazil Rheumatoid Arthritis Drugs Market by Route of Administration
9.5.5.2 Argentina Rheumatoid Arthritis Drugs Market
9.5.5.2.1 Argentina Rheumatoid Arthritis Drugs Market by Therapeutic Molecule
9.5.5.2.2 Argentina Rheumatoid Arthritis Drugs Market by Route of Administration
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Rest of the World
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. RHEUMATOID ARTHRITIS DRUGS MARKET, KEY COMPANY PROFILES
12.1. ABBVIE INC.
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. BOEHRINGER INGELHEIM GMBH
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. NOVARTIS AG
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. REGENERON PHARMACEUTICALS, INC.
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. PFIZER, INC.
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. JOHNSON AND JOHNSONS SERVICES, INC
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. BRISTOL-MYERS SQUIBB COMPANY
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. F. HOFFMANN-LA ROCHE LTD.
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. CELEGENE CORPORATIONS
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. MEDIMMUNE, LLC
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. AbbVie Inc.
2. Boehringer Ingelheim GmbH
3. Novartis AG
4. Regeneron Pharmaceuticals, Inc.
5. Pfizer, Inc.
6. Johnson & Johnsons Services, Inc
7. Bristol-Myers Squibb Company
8. F. Hoffmann-La Roche Ltd.
9. Celegene Corporations
10. MedImmune, LLC

TIPRE00013513
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking